Hudson Mollie, Todd Heather, Nalugwa Talemwa, Boccia Delia, Wingfield Tom, Shete Priya B
School of Nursing, University of California, San Francisco, San Francisco, USA.
Departments of Clinical Sciences and International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK.
Wellcome Open Res. 2023 Apr 18;8:175. doi: 10.12688/wellcomeopenres.18807.1. eCollection 2023.
Tuberculosis (TB) is a leading cause of death due to infectious disease worldwide. People with TB and their households often suffer social and economic losses due to the cost of tuberculosis care. The World Health Organization 2015 End TB strategy called for socioeconomic support through social protection interventions. Social protection has the potential to enable people with TB and their households to break the cycle of TB and poverty, thereby improving both treatment and socioeconomic outcomes. This study aims to evaluate whether people with TB who are recipients of social protection interventions have better treatment and socioeconomic outcomes than those who are not recipients of social protection interventions. We will systematically review literature published in English between 2012 and 2021 from PubMed, Embase, and Web of Science, and grey literature from Google Scholar and selected, relevant databases. We will include studies that describe a social protection intervention (as defined by the World Bank) and report on TB treatment outcomes and/or socioeconomic outcomes. We will only include studies pertaining to populations in low-and-middle-income countries and/or countries with high TB burden. We will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Study quality will be assessed using the Cochrane Risk of Bias for randomized controlled trials and the Newcastle Ottawa Scale for non-randomised controlled studies. If sufficient quantitative data are available, we will perform a meta-analysis of aggregated outcomes. Lastly, we will use the Grading Recommendations Assessment, Development, and Evaluation to describe the overall quality of evidence. Ethical approval is not required for this systematic review, as all data extraction and analysis will be conducted on published documents. We will disseminate this protocol through conference presentations. The systematic review has been registered prospectively in the PROSPERO database (registration number CRD42022382181).
结核病是全球因传染病导致死亡的主要原因。结核病患者及其家庭常常因结核病治疗费用而遭受社会和经济损失。世界卫生组织《2015年终结结核病战略》呼吁通过社会保护干预措施提供社会经济支持。社会保护有潜力使结核病患者及其家庭打破结核病与贫困的循环,从而改善治疗效果和社会经济成果。本研究旨在评估接受社会保护干预措施的结核病患者是否比未接受社会保护干预措施的患者有更好的治疗和社会经济成果。我们将系统回顾2012年至2021年期间发表在PubMed、Embase和科学网的英文文献,以及来自谷歌学术和选定的相关数据库的灰色文献。我们将纳入描述社会保护干预措施(如世界银行所定义)并报告结核病治疗结果和/或社会经济成果的研究。我们将仅纳入与低收入和中等收入国家及/或结核病负担高的国家的人群相关的研究。我们将遵循系统评价和荟萃分析的首选报告项目(PRISMA)指南。研究质量将使用Cochrane随机对照试验偏倚风险评估工具和非随机对照研究的纽卡斯尔渥太华量表进行评估。如果有足够的定量数据,我们将对汇总结果进行荟萃分析。最后,我们将使用推荐分级评估、制定和评价来描述证据的总体质量。由于所有数据提取和分析将基于已发表的文献进行,因此本系统评价无需伦理批准。我们将通过会议报告来传播本方案。该系统评价已在PROSPERO数据库中进行前瞻性注册(注册号CRD42022382181)。